ReviewEndocrine-related cancer2013
Metastatic mechanisms in follicular cell-derived thyroid cancer.
Review in Endocrine-related cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Overexpression of decorin gene influences the biological behaviors of follicular thyroid carcinoma cells.Oncology letters · 2025Article
- Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.The Journal of clinical endocrinology and metabolism · 2022Article
- Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases.Endocrine connections · 2021Article
- Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening.Cancers · 2020Article
- Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer.Frontiers in molecular biosciences · 2020Review
- Article
- Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy.Frontiers in endocrinology · 2019Article
- The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis.Nuclear medicine communications · 2018Article
- Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.Drug delivery · 2017Article
- Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm.Oncology & hematology review · 2017Article
- Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis.PloS one · 2017Article
- Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.The Journal of clinical endocrinology and metabolism · 2015Article
- Hypoxia Induces Epithelial-Mesenchymal Transition in Follicular Thyroid Cancer: Involvement of Regulation of Twist by Hypoxia Inducible Factor-1α.Yonsei medical journal · 2015Article
- [Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands].Der Pathologe · 2015Review
- Article
- Synchronous diagnosis of metastatic cancer to the thyroid is associated with poor prognosis.Endocrine pathology · 2015Article
- Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.The Journal of clinical endocrinology and metabolism · 2015Review
- Treatment of distant metastases from follicular cell-derived thyroid cancer.F1000prime reports · 2015Review
- Canonical transient receptor potential channel 2 (TRPC2): old name-new games. Importance in regulating of rat thyroid cell physiology.Pflugers Archiv : European journal of physiology · 2014Review
- NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma.Thyroid : official journal of the American Thyroid Association · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Thyroid cancer incidence is rising annually largely related to enhanced detection and early stage well-differentiated primary tumors. The prognosis for patients with early stage thyroid cancer is outstanding with most patients being cured with surgery. In selected cases, I-131 is administered to treat known or suspected residual or metastatic disease. Even patients with loco-regional metastases typically have an outstanding long-term prognosis, albeit with monitoring and occasional intervention for residual or recurrent disease. By contrast, individuals with distant metastases from thyroid cancer, particularly older patients with larger metastatic burdens and those with poorly differentiated tumors, have a poor prognosis. Patients with metastatic anaplastic thyroid cancer have a particularly poor prognosis. Published clinical trials indicate that transient disease control and partial remissions can be achieved with kinase inhibitor therapy directed toward angiogenic targets and that in some cases I-131 uptake can be enhanced. However, the direct targets of activity in metastatic lesions are incompletely defined and clear evidence that these treatments increase the duration or quality of life of patients is lacking, underscoring the need for improved knowledge regarding the metastatic process to inform the development of new therapies. In this review, we will focus on current data and hypotheses regarding key regulators of metastatic dormancy, metastatic progression, and the role of putative cancer stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.